21 October 2021
: Case report 
Treatment of Severe Immune Thrombocytopenic Purpura Associated with COVID-19
Challenging differential diagnosis, Unusual or unexpected effect of treatment, Educational Purpose (only if useful for a systematic review or synthesis), Rare coexistence of disease or pathology
Nayab Ahmed1AEF*, Abdullah Asreb1EF, Rosemary Chofor1EF, Achenef Melese1AEFDOI: 10.12659/AJCR.932557
Am J Case Rep 2021; 22:e932557
Table 1. Lab results on day of presentation.
| Reference range & units | Day 1 of hospital admission | |
|---|---|---|
| WBC | 4.8–10.8×10³/uL | 10.1 |
| RBC | 4.2–5.4 M/uL | 4.23 |
| Hemoglobin | 12–16 GM/dL | 11.6 |
| Hematocrit | 37–47% | 34.6 |
| MCV | 81–99 fL | 81.8 |
| MCH | 27–31 PG | 27.4 |
| MCHC | 33–37% | 33.5 |
| Platelets | 130–400×10³/uL | 0 |
| Immature platelet fraction | 1.1–7.1% | 34.1 |
| Protime | 9.4–12.5 s | 11.8 |
| INR | 0.85–1.13 | 1.04 |
| aPTT | 25.1–36.5 s | 27.2 |